Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126350131 | 12635013 | 1 | I | 1992 | 20160725 | 20160809 | 20160809 | EXP | US-ASTRAZENECA-2016SE83908 | ASTRAZENECA | 48.00 | YR | F | Y | 94.30000 | KG | 20160809 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126350131 | 12635013 | 1 | PS | ANASTRAZOLE | ANASTROZOLE | 1 | Oral | 1.0MG UNKNOWN | 20541 | 1 | MG | TABLET | |||||||
| 126350131 | 12635013 | 2 | SS | FELODIPINE. | FELODIPINE | 1 | Oral | U | 0 | PROLONGED-RELEASE TABLET | |||||||||
| 126350131 | 12635013 | 3 | SS | IMDUR | ISOSORBIDE MONONITRATE | 1 | Oral | 60.0MG UNKNOWN | 0 | 60 | MG | MODIFIED-RELEASE CAPSULE, HARD | |||||||
| 126350131 | 12635013 | 4 | SS | METOPROLOL ER | METOPROLOL SUCCINATE | 1 | Oral | 200.0MG UNKNOWN | 0 | 200 | MG | MODIFIED-RELEASE TABLET | |||||||
| 126350131 | 12635013 | 5 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | 0 | TABLET | |||||||||
| 126350131 | 12635013 | 6 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | 40 | MG | QD | |||||||||
| 126350131 | 12635013 | 7 | C | CHLOROTHALIDONE | 2 | 0 | 25 | MG | QD | ||||||||||
| 126350131 | 12635013 | 8 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | 0 | 75 | MG | QD | |||||||||
| 126350131 | 12635013 | 9 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 0 | 25 | MG | QD | |||||||||
| 126350131 | 12635013 | 10 | C | GLIPIZIDE. | GLIPIZIDE | 1 | 0 | 10 | MG | QD | |||||||||
| 126350131 | 12635013 | 11 | C | TRIGLYCERIDES | 2 | 0 | |||||||||||||
| 126350131 | 12635013 | 12 | C | LOSARTAN. | LOSARTAN | 1 | 0 | 50 | MG | BID | |||||||||
| 126350131 | 12635013 | 13 | C | JANUMET | METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE | 1 | 0 | ||||||||||||
| 126350131 | 12635013 | 14 | C | KOMBIGLYZE XR | METFORMIN HYDROCHLORIDESAXAGLIPTIN HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126350131 | 12635013 | 6 | Gastrooesophageal reflux disease |
| 126350131 | 12635013 | 7 | Blood pressure abnormal |
| 126350131 | 12635013 | 9 | Blood pressure abnormal |
| 126350131 | 12635013 | 10 | Blood cholesterol abnormal |
| 126350131 | 12635013 | 12 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126350131 | 12635013 | OT |
| 126350131 | 12635013 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126350131 | 12635013 | Aortic aneurysm | |
| 126350131 | 12635013 | Breast cancer | |
| 126350131 | 12635013 | Burning sensation | |
| 126350131 | 12635013 | Cardiac disorder | |
| 126350131 | 12635013 | Diabetes mellitus | |
| 126350131 | 12635013 | Gastrooesophageal reflux disease | |
| 126350131 | 12635013 | Hypertension | |
| 126350131 | 12635013 | Intentional product misuse | |
| 126350131 | 12635013 | Renal failure | |
| 126350131 | 12635013 | Skin cancer | |
| 126350131 | 12635013 | Vein disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126350131 | 12635013 | 6 | 2015 | 0 | ||
| 126350131 | 12635013 | 7 | 2015 | 0 | ||
| 126350131 | 12635013 | 9 | 2015 | 0 |